1
|
Xia YL, Wang JJ, Li SY, Liu Y, Gonzalez FJ, Wang P, Ge GB. Synthesis and structure-activity relationship of coumarins as potent Mcl-1 inhibitors for cancer treatment. Bioorg Med Chem 2021; 29:115851. [PMID: 33218896 PMCID: PMC7855844 DOI: 10.1016/j.bmc.2020.115851] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2020] [Revised: 10/16/2020] [Accepted: 11/01/2020] [Indexed: 12/24/2022]
Abstract
Myeloid cell leukemia-1 (Mcl-1) is a validated and attractive target for cancer therapy. Over-expression of Mcl-1 in many cancers allows cancer cells to evade apoptosis and contributes to their resistance to current chemotherapeutics. In this study, more than thirty coumarin derivatives with different substituents were designed and synthesized, and their Mcl-1 inhibitory activities evaluated using a fluorescence polarization-based binding assay. The results showed that the catechol group was a key constituent for Mcl-1 inhibitory activity of the coumarins, and methylation of the catechol group led to decreased inhibitory activity. The introduction of a hydrophobic electron-withdrawing group at the C-4 position of 6,7-dihydroxycoumarin, enhanced Mcl-1 inhibitory capacity, and a hydrophilic group in this position was unbeneficial to the inhibitory potency. In addition, the introduction of a nitrogen-containing group to the C-5 or C-8 position, which allowed an intramolecular hydrogen bond, was also unfavorable for Mcl-1 inhibition. Among all coumarins tested, 4-trifluoromethyl-6,7-dihydroxycoumarin (Cpd 4) displayed the most potent inhibitory activity towards Mcl-1 (Ki = 0.21 ± 0.02 μM, IC50 = 1.21 ± 0.56 μM, respectively), for which the beneficial effect on taxol resistance was also validated in A549 cells. A strong interaction between Cpd 4 and Mcl-1 in docking simulations further supported the observed potent Mcl-1 inhibition ability of Cpd 4. 3D-QSAR analysis of all tested coumarin derivatives further provides new insights into the relationships linking the inhibitory effects on Mcl-1 and the steric-electrostatic properties of coumarins. These findings could be of great value for medicinal chemists for the design and development of more potent Mcl-1 inhibitors for biomedical applications.
Collapse
Affiliation(s)
- Yang-Liu Xia
- School of Life Science and Medicine, Dalian University of Technology, Panjin 124221, China; Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Jing-Jing Wang
- School of Life Science and Medicine, Dalian University of Technology, Panjin 124221, China
| | - Shi-Yang Li
- Analytical Central Laboratory, Shengyang Harmony Health Medical Laboratory Co Ltd, Shenyang 210112, China
| | - Yong Liu
- School of Life Science and Medicine, Dalian University of Technology, Panjin 124221, China
| | - Frank J Gonzalez
- Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Ping Wang
- Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
| | - Guang-Bo Ge
- Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
| |
Collapse
|
3
|
Besbes S, Mirshahi M, Pocard M, Billard C. New dimension in therapeutic targeting of BCL-2 family proteins. Oncotarget 2016; 6:12862-71. [PMID: 25970783 PMCID: PMC4536985 DOI: 10.18632/oncotarget.3868] [Citation(s) in RCA: 86] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2015] [Accepted: 04/01/2015] [Indexed: 01/22/2023] Open
Abstract
Proteins of the BCL-2 family control the mitochondrial pathway of apoptosis. Targeting these proteins proves to be an attractive strategy for anticancer therapy. The biological context is based on the fact that BH3-only members of the family are specific antagonists of prosurvival members. This prompted the identification of “BH3 mimetic” compounds. These small peptides or organic molecules indeed mimic the BH3 domain of BH3-only proteins: by selectively binding and antagonizing prosurvival proteins, they can induce apoptosis in malignant cells. Some small-molecule inhibitors of prosurvival proteins have already entered clinical trials in cancer patients and two of them have shown significant therapeutic effects. The latest developments in the field of targeting BCL-2 family proteins highlight several new antagonists of prosurvival proteins as well as direct activators of proapoptotic proteins. These compounds open up novel prospects for the development of BH3 mimetic anticancer drugs.
Collapse
Affiliation(s)
- Samaher Besbes
- INSERM U 965, Hôpital Lariboisière, Paris, France.,Université Paris Diderot, UMR S965, Paris, France
| | - Massoud Mirshahi
- INSERM U 965, Hôpital Lariboisière, Paris, France.,Université Paris Diderot, UMR S965, Paris, France
| | - Marc Pocard
- INSERM U 965, Hôpital Lariboisière, Paris, France.,Université Paris Diderot, UMR S965, Paris, France
| | - Christian Billard
- INSERM U 965, Hôpital Lariboisière, Paris, France.,Université Paris Diderot, UMR S965, Paris, France
| |
Collapse
|
4
|
Bruncko M, Wang L, Sheppard GS, Phillips DC, Tahir SK, Xue J, Erickson S, Fidanze S, Fry E, Hasvold L, Jenkins GJ, Jin S, Judge RA, Kovar PJ, Madar D, Nimmer P, Park C, Petros AM, Rosenberg SH, Smith ML, Song X, Sun C, Tao ZF, Wang X, Xiao Y, Zhang H, Tse C, Leverson JD, Elmore SW, Souers AJ. Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity. J Med Chem 2015; 58:2180-94. [DOI: 10.1021/jm501258m] [Citation(s) in RCA: 113] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Milan Bruncko
- AbbVie Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064, United States
| | - Le Wang
- AbbVie Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064, United States
| | - George S. Sheppard
- AbbVie Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064, United States
| | - Darren C. Phillips
- AbbVie Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064, United States
| | - Stephen K. Tahir
- AbbVie Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064, United States
| | - John Xue
- AbbVie Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064, United States
| | - Scott Erickson
- AbbVie Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064, United States
| | - Steve Fidanze
- AbbVie Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064, United States
| | - Elizabeth Fry
- AbbVie Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064, United States
| | - Lisa Hasvold
- AbbVie Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064, United States
| | - Gary J. Jenkins
- AbbVie Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064, United States
| | - Sha Jin
- AbbVie Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064, United States
| | - Russell A. Judge
- AbbVie Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064, United States
| | - Peter J. Kovar
- AbbVie Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064, United States
| | - David Madar
- AbbVie Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064, United States
| | - Paul Nimmer
- AbbVie Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064, United States
| | - Chang Park
- AbbVie Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064, United States
| | - Andrew M. Petros
- AbbVie Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064, United States
| | - Saul H. Rosenberg
- AbbVie Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064, United States
| | - Morey L. Smith
- AbbVie Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064, United States
| | - Xiaohong Song
- AbbVie Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064, United States
| | - Chaohong Sun
- AbbVie Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064, United States
| | - Zhi-Fu Tao
- AbbVie Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064, United States
| | - Xilu Wang
- AbbVie Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064, United States
| | - Yu Xiao
- AbbVie Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064, United States
| | - Haichao Zhang
- AbbVie Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064, United States
| | - Chris Tse
- AbbVie Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064, United States
| | - Joel D. Leverson
- AbbVie Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064, United States
| | - Steven W. Elmore
- AbbVie Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064, United States
| | - Andrew J. Souers
- AbbVie Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064, United States
| |
Collapse
|
5
|
Foight GW, Ryan JA, Gullá SV, Letai A, Keating AE. Designed BH3 peptides with high affinity and specificity for targeting Mcl-1 in cells. ACS Chem Biol 2014; 9:1962-8. [PMID: 25052212 PMCID: PMC4168798 DOI: 10.1021/cb500340w] [Citation(s) in RCA: 76] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Mcl-1 is overexpressed in many cancers and can confer resistance to cell-death signaling in refractory disease. Molecules that specifically inhibit Mcl-1 hold potential for diagnosing and disrupting Mcl-1-dependent cell survival. We selected three peptides from a yeast-surface display library that showed moderate specificity and affinity for binding to Mcl-1 over Bfl-1, Bcl-xL, Bcl-2, and Bcl-w. Specificity for Mcl-1 was improved by introducing threonine at peptide position 2e. The most specific peptide, MS1, bound Mcl-1 with 40-fold or greater specificity over four other human Bcl-2 paralogs. In BH3 profiling assays, MS1 caused depolarization in several human Mcl-1-dependent cell lines with EC50 values of ∼3 μM, contrasted with EC50 values of >100 μM for Bcl-2-, Bcl-xL-, or Bfl-1-dependent cell lines. MS1 is at least 30-fold more potent in this assay than the previously used Mcl-1 targeting reagent NoxaA BH3. These peptides can be used to detect Mcl-1 dependency in cells and provide leads for developing Mcl-1 targeting therapeutics.
Collapse
Affiliation(s)
- Glenna Wink Foight
- Department
of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| | - Jeremy A. Ryan
- Department
of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States
| | - Stefano V. Gullá
- Department
of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| | - Anthony Letai
- Department
of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States
- Department
of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States
| | - Amy E. Keating
- Department
of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
6
|
Friberg A, Vigil D, Zhao B, Daniels RN, Burke JP, Garcia-Barrantes PM, Camper D, Chauder BA, Lee T, Olejniczak ET, Fesik SW. Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design. J Med Chem 2013; 56:15-30. [PMID: 23244564 PMCID: PMC3646517 DOI: 10.1021/jm301448p] [Citation(s) in RCA: 219] [Impact Index Per Article: 19.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Myeloid cell leukemia 1 (Mcl-1), a member of the Bcl-2 family of proteins, is overexpressed and amplified in various cancers and promotes the aberrant survival of tumor cells that otherwise would undergo apoptosis. Here we describe the discovery of potent and selective Mcl-1 inhibitors using fragment-based methods and structure-based design. NMR-based screening of a large fragment library identified two chemically distinct hit series that bind to different sites on Mcl-1. Members of the two fragment classes were merged together to produce lead compounds that bind to Mcl-1 with a dissociation constant of <100 nM with selectivity for Mcl-1 over Bcl-xL and Bcl-2. Structures of merged compounds when complexed to Mcl-1 were obtained by X-ray crystallography and provide detailed information about the molecular recognition of small-molecule ligands binding Mcl-1. The compounds represent starting points for the discovery of clinically useful Mcl-1 inhibitors for the treatment of a wide variety of cancers.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Stephen W. Fesik
- Corresponding author; Phone, +1 (615) 322 6303; Fax, +1 (615) 875 3236
| |
Collapse
|